СИНДРОМ РАЗДРАЖЕННОГО КИШЕЧНИКА И МИКРОБИОТА: ПУТИ ОПТИМИЗАЦИИ ТЕРАПИИ

Скачать статью в PDF
Номер журнала: 
5
Год издания: 
2015

М.А. Осадчук (1), доктор медицинских наук, профессор, М.М. Осадчук (2), кандидат медицинских наук 1 -Первый МГМУ им. И.М. Сеченова 2 -Городская поликлиника № 52 Департамента здравоохранения Москвы E-mail: osadchuk.mikhail@yandex.ru

Представлен аналитический обзор, посвященный роли микрофлоры кишечника в формировании синдрома раздраженного кишечника (СРК). Не вызывает сомнения то, что микрофлора кишечника может инициировать симптомы СРК, изменяя нейромоторные сенсорные, барьерные функции кишечника и их взаимодействие по оси мозг– кишечник.
Ключевые слова: 
синдром раздраженного кишечника
микробиота
пробиотические препараты
Линекс®
Для цитирования
Осадчук М.А., Осадчук М.М. СИНДРОМ РАЗДРАЖЕННОГО КИШЕЧНИКА И МИКРОБИОТА: ПУТИ ОПТИМИЗАЦИИ ТЕРАПИИ . Врач, 2015; (5): 47-51

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. Захаренко С.М. Антибиотики и пробиотики: конкуренты или синергисты? // Эпидем. и инфекцион. бол. – 2007; 5 (1): 47–53.
  2. Осадчук М.А., Свистунов А.А.. Антибиотикоассоциированная диарея в клиничес-кой практике // Вопр. соврем. педиатрии. – 2014; 13 (1); 102–8.
  3. Парфенов А.И., Ручкина И.Н., Атауллаханов Р.И. Постинфекционный синдром раздраженного кишечника. Особенности патогенеза, диагностики и лечения // Рус. мед. журн. – 2009; 11 (2): 1–5.
  4. Amaral F., Sachs D., Costa V. et al. Commensal microbiota is fundamental for the development of inflammatory pain // Proc. Natl. Acad. Sci. USA. – 2008; 105: 2193–7.
  5. Asano Y., Hiramoto T., Nishino R. et al. Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice // Am. J. Physiol. Gastrointest. Liver Physiol. – 2012; 303: 1288–95.
  6. Lyte M. Microbial endocrinology and infectious disease in the 21st century // Trends Microbiol. – 2004; 12: 14–20.
  7. Belmonte L., Beutheu-Youmba S., Bertiaux-Vanda ële N. et al. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype // PLoS One. – 2012; 7: 42777.
  8. Bindels L., Dewulf E., Delzenne N. GPR43/FFA2: physiopathological relevance and therapeutic prospects // Trends Pharmacol. Sci. – 2013; 34: 226–32.
  9. Bouhnik Y., Alain S., Attar A. et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome // Am. J. Gastroenterol. – 1999; 94: 1327–31.
  10. Buhner S., Li Q., Vignali S. et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome // Gastroenterology. – 2009; 137: 1425–34.
  11. Carroll I., Ringel-Kulka T., Siddle J. et al. Characterization of the fecal microbiota using high-throughput sequencing reveals a stable microbial community during storage // PLoS One. – 2012; 7: 46953.
  12. Chalmers N., Palmer R., Cisar J. et al. Characterization of a Streptococcus spр. – Veillonella spр. community micromanipulated from dental plaque // J. Bacteriol. – 2008; 190: 8145–54.
  13. Cogan T., Thomas A., Rees L. et al. Norepinephrine increases the pathogenic potential of Campylobacter jejuni // Gut. – 2007; 56: 1060–5.
  14. Faith J., Guruge J., Charbonneau M. et al. The long-term stability of the human gut microbiota // Science. – 2013; 341: 1237439.
  15. Fukudo S. Pathogenesis of irritable bowel syndrome // Nihon Shokakibyo Gakkai Zasshi. – 2014; 111 (7): 1323–33
  16. Guglielmetti S., Mora D., Gschwender M. et al. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study // Aliment. Pharmacol. Ther. – 2011; 33: 1123–32.
  17. Ivanov D., Emonet C., Foata F. et al. A serpin from the gut bacterium Bifidobacteriumlongum inhibits eukaryotic elastase-like serine proteases // J. Biol. Chem. – 2006; 281: 17246–52.
  18. Jeffery I., O’Toole P., 18. Öhman L. et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota // Gut. – 2012; 61: 997–1006.
  19. Lekha Saha. Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine // World J. Gastroenterol. – 2014; 20 (22): 6759–73.
  20. Liebregts T., Adam B., Bredack C. et al. Immune activation in patients with irritable bowel syndrome. Immune activation in patients with irritable bowel syndrome // Gastroenterology. – 2007; 132: 913–20.
  21. Lyra A., Rinttil21. ä T., Nikkilä J. et al. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification // World J. Gastroenterol. – 2009; 15: 5936–45.
  22. Lyte M. Microbial endocrinology and infectious disease in the 21st century . // Trends Microbiol. – 2004; 12: 14–20
  23. Lyte M., Freestone P. Microbial Endocrinology: interkingdom signaling in health and disease. Springer Publishers; 2010.
  24. Macfarlane G., Allison C., Gibson S. et al. Contribution of the microflora to . proteolysis in the human large intestine // J. Appl. Bacteriol. – 1988; 64: 37–46.
  25. Macfarlane S., Woodmansey E., Macfarlane G. Colonization of mucin by human intestinal bacteria and establishment of biofilm communities in a two-stage continuous culture system // Appl. Environ. Microbiol. – 2005; 71: 7483–92.
  26. Malinen E., Rinttil26. ä T., Kajander K. et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR // Am. J. Gastroenterol. – 2005; 100: 373–82.
  27. Matricon J., Meleine M., Gelot A. et al. Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome // Aliment. Pharmacol. Ther. – 2012; 36: 1009–31.
  28. Milani C., Hevia A., Foroni E. et al. Assessing the fecal microbiota: an optimized ion torrent 16S rRNA gene-based analysis protocol // PLoS One. – 2013; 8 (7): 68739
  29. Nam Y., Jung M., Roh S. et al. Comparative analysis of Korean human gut microbiota by barcoded pyrosequencing // PLoS One. – 2011; 6: 22109.
  30. Nohr M., Pedersen M., Gille A. et al. GPR41/FFAR3 and GPR43/FFAR2 as Cosensors for Short-Chain Fatty Acids in Enteroendocrine Cells vs FFAR3 in Enteric Neurons and FFAR2 in Enteric Leukocytes // Endocrinology. – 2013; 154: 3552
  31. Paliy O., Kenche H., Abernathy F. et al. High-throughput quantitative analysis of the human intestinal microbiota with a phylogenetic microarray // Appl. Environ. Microbiol. – 2009; 75: 3572–9.
  32. Parkes G., Sanderson J., Whelan K. Treating irritable bowel syndrome with probiotics: the evidence // Proc. Nutr. Soc. – 2010; 69: 187–94.
  33. Parkes G., Rayment N., Hudspith B. et al. Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome // Neurogastroenterol. Motil. – 2012; 24: 31–9.
  34. Qin J., Li R., Raes J. et al. A human gut microbial gene catalogue established by metagenomic sequencing // Nature. – 2010; 464: 59–65.
  35. Quigley E., Craig O. Irritable bowel syndrome; update on pathophysiology and management // Turk. J. Gastroenterol. – 2012; 23 (4): 313–22.
  36. Rajili36. -Stojanovi M., Biagi E., Heilig H. et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome // Gastroenterology. – 2011; 141: 1792–801.
  37. Rajili37. -Stojanovi M. Diversity of the Human Gastrointestinal Microbiota-Novel Perspectives from High Throughput Analyses [PhD thesis] / Wageningen: Wageningen University, 2007.
  38. Rigsbee L., Agans R., Shankar V. et al. Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome // Am. J. Gastroenterol. – 2012; 107 (11): 1740–51.
  39. Sanders M., Guarner F., Guerrant R. et al. An update on the use and investigation of probiotics in health and disease // Gut. – 2013; 62: 787–96.
  40. Santos J., Saperas E., Nogueiras C. et al. Release of mast cell mediators into the jejunum by cold pain stress in humans // Gastroenterology. – 1998; 114: 640–8.
  41. Simr41. én M., Barbara G., Flint H. et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report // Gut. – 2013; 62 (1): 159–76.
  42. Sommer F., Bäckhed F. The gut microbiota--masters of host development and physiology // Nat. Rev. Microbiol. – 2013; 11: 227–38.
  43. Spiegel B. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective // Clin. Gastroenterol. Hepatol. – 2011; 9: 461–9.
  44. Spiller R., Garsed K. Postinfectious irritable bowel syndrome // Gastroenterology. – 2009; 136: 1979–88.
  45. Tana C., Umesaki Y., Imaoka A. et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome // Neurogastroenterol. Motil. – 2010; 22: 512–9, e114–5.
  46. Thompson W., Longstreth G., Drossman D. et al. Functional bowel disorders and functional abdominal pain // Gut. – 1999; 45 (Suppl. 2): 43–7.
  47. Saulnier D., Riehle K., Mistretta T. et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome // Gastroenterology. – 2011; 141: 1782–91.
  48. Wilson S., Roberts L., Roalfe A. et al. Prevalence of irritable bowel syndrome: a community survey // Br. J. Gen. Pract. – 2004; 54: 495–502.
  49. Yang H., Stephens R., Tache Y. TRH analogue microinjected into specific medullary nuclei stimulates gastric serotonin secretion in rats // Am. J. Physiol. – 1992; 262(2 Pt 1): 216–22.
  50. Сухорукова М.В., Тимохова А.В., Эйдельштейн М.В. и др. Чувствительность к антибиотикам штаммов бактерий, входящих в состав про-биотика Линекс® // Клин. микробиол. и антимикроб. химиотер. – 2012; 14 (3): 248–51.